GH Guardant Health, Inc. Stock Quote

GH [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-3.77	Insider Own	3.60%	Shs Outstand	101.17M	Perf Week	1.44%
Market Cap	10.92B	Forward P/E	-	EPS next Y	-3.34	Insider Trans	-3.29%	Shs Float	96.79M	Perf Month	-18.66%
Income	-378.60M	PEG	-	EPS next Q	-0.96	Inst Own	90.70%	Short Float	4.78%	Perf Quarter	-11.87%
Sales	323.70M	P/S	33.73	EPS this Y	-211.70%	Inst Trans	0.11%	Short Ratio	5.11	Perf Half Y	-31.24%
Book/sh	7.79	P/B	13.49	EPS next Y	14.80%	ROA	-18.50%	Target Price	167.39	Perf Year	2.26%
Cash/sh	17.24	P/C	6.09	EPS next 5Y	12.60%	ROE	-37.60%	52W Range	96.66 - 181.07	Perf YTD	-18.48%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-12.10%	52W High	-41.98%	Beta	-
Dividend %	-	Quick Ratio	19.30	Sales past 5Y	-	Gross Margin	66.50%	52W Low	8.69%	ATR	5.45
Employees	864	Current Ratio	19.60	Sales Q/Q	38.90%	Oper. Margin	-	RSI (14)	40.86	Volatility	4.40% 5.00%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-69.50%	Profit Margin	-	Rel Volume	1.83	Prev Close	99.44
Shortable	Yes	LT Debt/Eq	1.44	Earnings	Nov 04 AMC	Payout	-	Avg Volume	905.00K	Price	105.06
Recom	1.50	SMA20	-7.40%	SMA50	-9.67%	SMA200	-20.87%	Volume	1,659,446	Change	5.65%

Oct-15-21

Resumed

Cowen

Outperform

$170

Jun-15-21

Initiated

Raymond James

Mkt Perform

Jun-03-21

Initiated

Goldman

Buy

$160

May-25-21

Initiated

Wells Fargo

Overweight

$145

Jan-11-21

Initiated

Stifel

Buy

$175

Sep-09-20

Initiated

Morgan Stanley

Overweight

$110

Jun-12-20

Initiated

BTIG Research

Buy

Feb-21-20

Initiated

Guggenheim

Buy

$103

Jan-07-20

Initiated

Citigroup

Buy

$100

Aug-07-19

Reiterated

Canaccord Genuity

Buy

$96 → $125

Apr-16-19

Initiated

Canaccord Genuity

Buy

$90

Apr-10-19

Upgrade

BofA/Merrill

Neutral → Buy

$81 → $84

Feb-28-19

Reiterated

BofA/Merrill

Neutral

$42 → $60

Oct-29-18

Initiated

William Blair

Outperform

Oct-29-18

Initiated

JP Morgan

Overweight

$42

Oct-29-18

Initiated

BofA/Merrill

Neutral

$37

Oct-08-21 08:05AM	Guardant Health to Report Third Quarter Financial Results on November 4, 2021 Business Wire -6.51%
Oct-05-21 08:05AM	Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal Blood Test to Predict Recurrence Across Early-Stage Cancers Business Wire
Oct-04-21 12:04PM	Here is What Hedge Funds Think About Guardant Health, Inc. (GH) Insider Monkey
Oct-03-21 10:40AM	Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet? Simply Wall St.
Oct-01-21 01:13PM	Why Guardant Health Is Down More Than 14% Friday Motley Fool -14.00%
12:41PM	35 Stocks Moving In Friday's Mid-Day Session Benzinga
09:40AM	Guardant Said to Weigh Deal For Diagnostics Firm NeoGenomics Bloomberg
Sep-30-21 06:13AM	Investing in These 2 Top Stocks Could Make You a Millionaire Retiree Motley Fool
Sep-27-21 11:45AM	SoftBank Vision Funds Deep Nishar to Leave at End of Year Bloomberg
Sep-17-21 12:00AM	Carillon Tower Advisers: Guardant (GH) Remains One of the Unquestioned Leaders in its Space Insider Monkey
Sep-15-21 04:00AM	Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers Business Wire
Sep-08-21 01:34PM	SoftBank Vision Funds Deep Nishar Is Discussing Leaving Firm Bloomberg
Sep-07-21 08:05AM	New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer GlobeNewswire
Sep-02-21 04:05PM	Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference GlobeNewswire
Aug-31-21 12:07AM	Is Guardant Health (GH) A Good Stock To Buy Now? Insider Monkey
Aug-18-21 02:23PM	Baron Funds: Guardant (GH) is a Unique Growth Company Insider Monkey
Aug-17-21 09:25PM	SoftBank Sold About $14 Billion in Listed Stocks Last Quarter Bloomberg
Aug-12-21 01:05PM	Alger Small Cap Focus Fund: We Continue to Have High Conviction in Guardant Health (GH) Insider Monkey
Aug-11-21 04:30AM	Barrons Worst: Coinbase, PetIQ, and 3 More Stock Picks That Did Nothing But Drop Barrons.com
Aug-06-21 04:15PM	Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Business Wire
10:30AM	Guardant Health, inc (GH) Q2 2021 Earnings Call Transcript Motley Fool
09:35AM	Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates Benzinga
Aug-05-21 06:35PM	Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors Business Wire
04:03PM	Guardant Health Reports Second Quarter 2021 Financial Results Business Wire
Aug-01-21 05:52AM	Missed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead. Motley Fool
Jul-29-21 03:05PM	Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline Zacks
Jul-19-21 06:38PM	AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round PR Newswire
09:30AM	AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round PR Newswire
Jul-13-21 08:05AM	Guardant Health to Report Second Quarter Financial Results on August 5, 2021 Business Wire
Jul-05-21 03:42AM	Did Guardant Health's (NASDAQ:GH) Share Price Deserve to Gain 49%? Simply Wall St.
Jun-30-21 11:17AM	This Explosive Biotech Is Taking On a Huge New Market Motley Fool
Jun-25-21 12:28PM	Is Guardant Health (GH) A Smart Long-Term Buy? Insider Monkey
Jun-23-21 01:25PM	Here is What Hedge Funds Think About Guardant Health, Inc. (GH) Insider Monkey
Jun-22-21 08:05AM	Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling Business Wire
Jun-18-21 08:23PM	CORRECTING and REPLACING Study Shows Guardant Reveal Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity Business Wire
07:57PM	CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers Business Wire
Jun-08-21 08:05AM	Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer Business Wire
Jun-04-21 09:10AM	Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer Business Wire
May-28-21 01:15PM	Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgens LUMAKRAS (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer Business Wire
01:52AM	Guardant Health Files Lawsuit Against Natera for Misleading Oncologists Business Wire
May-22-21 06:11AM	With Expenses Growing Faster Than Revenue, Is This Cathie Wood Stock in Trouble? Motley Fool
May-21-21 03:14PM	Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssens RYBREVANT (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Business Wire
May-20-21 04:17PM	Guardant Had Colon Cancer Data, But Rival Exact Popped Here's Why Investor's Business Daily
03:51PM	Why Exact Sciences Stock Soared Today Motley Fool
08:05AM	Guardant Health to Participate in Upcoming June Investor Conferences Business Wire
May-15-21 06:39AM	Exact Sciences' First-Quarter Results Show Its Strength Under Pressure Motley Fool
May-13-21 06:16AM	3 Cathie Wood Stocks for a $150 Billion Market That's Just Forming Motley Fool
May-07-21 06:00AM	Guardant Health Inc (GH) Q1 2021 Earnings Call Transcript Motley Fool
May-06-21 06:50PM	Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates Zacks
May-04-21 04:02PM	Was The Smart Money Right About Piling Into Guardant Health (GH)? Insider Monkey
May-03-21 08:05AM	Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer Business Wire
Apr-29-21 05:06PM	Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for Zacks
08:05AM	Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference Business Wire
Apr-27-21 08:05AM	Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer Business Wire
Apr-24-21 06:12AM	Disruptor Alert: These 2 Companies Are Changing Cancer Care Motley Fool
Apr-12-21 04:05PM	Guardant Health to Report First Quarter Financial Results on May 6, 2021 Business Wire
07:26AM	How a Simple Blood Test Could Reduce Cancer Deaths Barrons.com
Apr-10-21 08:35AM	Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers Business Wire
Apr-06-21 11:11AM	Bear of the Day: Guardant Health (GH) Zacks
05:05AM	Is Guardant Health (NASDAQ:GH) Using Debt In A Risky Way? Simply Wall St.
Apr-01-21 11:05AM	Why Guardant Health Stock Is Rising Today Motley Fool
08:05AM	Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer Business Wire
06:57AM	Better Buy for the Next 10 Years: Abiomed vs. Guardant Heath Motley Fool
Mar-30-21 08:05AM	Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx Test Business Wire +5.96%
Mar-26-21 08:05AM	Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer Business Wire
Mar-25-21 07:01AM	Why Guardant Health Should Be a Big Winner Over the Long Term Motley Fool
Mar-24-21 08:05AM	Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer Business Wire -5.92%
Mar-23-21 10:02AM	Is Guardant Health (GH) Stock A Buy or Sell? Insider Monkey
Mar-21-21 07:33AM	3 Extraordinary Diagnostics Stocks for 2021 Motley Fool
Mar-13-21 07:18AM	Should Investors Be Worried About Guardant Health's Slowdown? Motley Fool
Mar-04-21 03:21PM	Why Guardant Health Stock Sank Today Motley Fool -7.34%
Mar-03-21 08:17AM	Like Guardant Health? You'll Love CareDx Motley Fool -7.07%
Mar-02-21 08:05AM	Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers Business Wire
Mar-01-21 09:20AM	New Strong Sell Stocks for March 1st Zacks
Feb-25-21 11:34AM	Why Guardant Health Stock Is Sinking Today Motley Fool -7.88%
06:04AM	What's Behind Guardant Health's Disappointing Q4 Results Motley Fool
12:30AM	Guardant Health Inc (GH) Q4 2020 Earnings Call Transcript Motley Fool
Feb-24-21 04:29PM	Guardant Health: Q4 Earnings Insights Benzinga
04:05PM	Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021 Business Wire
Feb-23-21 10:24AM	Guardant Health Earnings Preview Benzinga
Feb-21-21 06:17AM	Adding $5,000 to These 2 Top Stocks Could Make You Richer in 2021 (and Beyond) Motley Fool
06:12AM	2 Fantastic Growth Stocks to Buy Right Now Motley Fool
Feb-17-21 04:03PM	Guardant Health to Participate in Upcoming Investor Conferences Business Wire
Feb-16-21 08:05AM	Guardant Health Launches Guardant Reveal Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer Business Wire
Feb-12-21 06:01AM	3 Revolutionary Stocks That Can Make You Rich Motley Fool +6.41%
Feb-05-21 05:52AM	3 No-Brainer Stocks to Buy That Should Soar This Year Motley Fool
Feb-04-21 04:03PM	Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 Business Wire
Feb-03-21 06:10AM	Ignore GameStop: Here Are 3 Better Stocks Motley Fool
Jan-29-21 06:08AM	3 Game-Changing Stocks to Buy and Hold for 10 Years or More Motley Fool
Jan-27-21 08:05AM	Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar Outcomes Business Wire
Jan-25-21 06:01AM	Why I'm Betting Big on This 1 Megatrend Motley Fool
Jan-18-21 03:00AM	Guardant Health and Vall dHebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe Business Wire
Jan-14-21 08:05AM	Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer Business Wire
Jan-13-21 07:25AM	The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga
Jan-07-21 01:18PM	12 Best Telemedicine Stocks to Buy Now Insider Monkey +6.81%
Jan-06-21 02:47AM	What Type Of Shareholders Make Up Guardant Health, Inc.'s (NASDAQ:GH) Share Registry? Simply Wall St.
Dec-30-20 04:03PM	Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-20 07:31AM	The 3 Best Healthcare Stocks to Buy for 2021 Motley Fool
Dec-24-20 10:21AM	Stocks This Hot Goldman Sachs Fund Likes Besides Amazon, Apple, Netflix Investor's Business Daily

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MERESMAN STANLEY J	Director	Oct 11	Option Exercise	5.94	4,934	29,308	8,993	Oct 13 05:03 PM
MERESMAN STANLEY J	Director	Oct 11	Sale	103.59	4,934	511,113	4,059	Oct 13 05:03 PM
MERESMAN STANLEY J	Director	Sep 10	Option Exercise	5.94	4,934	29,308	8,993	Sep 14 05:07 PM
MERESMAN STANLEY J	Director	Sep 10	Sale	129.78	4,934	640,331	4,059	Sep 14 05:07 PM
CLARK IAN T	Director	Sep 01	Option Exercise	4.18	1,076	4,498	1,076	Sep 03 05:06 PM
CLARK IAN T	Director	Sep 01	Sale	130.00	1,076	139,880	0	Sep 03 05:06 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Aug 13	Option Exercise	4.18	23,923	99,998	1,851,686	Aug 17 07:02 PM
Talasaz AmirAli	Co-Chief Executive Officer	Aug 13	Option Exercise	4.18	23,923	99,998	1,749,345	Aug 17 07:02 PM
MERESMAN STANLEY J	Director	Aug 10	Option Exercise	5.94	4,934	29,308	8,993	Aug 12 05:08 PM
MERESMAN STANLEY J	Director	Aug 10	Sale	114.31	4,934	564,006	4,059	Aug 12 05:08 PM
MERESMAN STANLEY J	Director	Jul 12	Option Exercise	5.94	4,934	29,308	8,993	Jul 14 05:01 PM
MERESMAN STANLEY J	Director	Jul 12	Sale	124.27	4,934	613,148	4,059	Jul 14 05:01 PM
CLARK IAN T	Director	Jun 29	Option Exercise	63.83	5,916	377,613	10,559	Jul 01 05:04 PM
CLARK IAN T	Director	Jun 29	Sale	130.00	10,559	1,372,670	0	Jul 01 05:04 PM
MERESMAN STANLEY J	Director	Jun 10	Option Exercise	5.94	4,934	29,308	8,993	Jun 14 05:02 PM
MERESMAN STANLEY J	Director	Jun 10	Sale	113.60	4,934	560,502	4,059	Jun 14 05:02 PM
MERESMAN STANLEY J	Director	May 10	Option Exercise	5.94	4,934	29,308	8,993	May 12 05:22 PM
MERESMAN STANLEY J	Director	May 10	Sale	133.01	4,934	656,271	4,059	May 12 05:22 PM
Kaul Samir	Director	May 05	Sale	142.85	5,000	714,242	14,943	May 07 04:41 PM
CLARK IAN T	Director	Apr 26	Option Exercise	4.18	538	2,249	5,181	Apr 28 06:16 PM
CLARK IAN T	Director	Apr 26	Sale	159.92	538	86,037	4,643	Apr 28 06:16 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 26	Sale	160.01	751	120,167	1,827,763	Apr 26 05:35 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 23	Sale	160.12	7,388	1,182,993	1,828,514	Apr 26 05:35 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 21	Sale	151.76	56,358	8,552,690	1,835,902	Apr 22 06:43 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 20	Sale	150.75	16,007	2,413,000	1,892,260	Apr 22 06:43 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 19	Sale	152.97	50,932	7,790,914	1,908,267	Apr 19 07:14 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 16	Sale	158.34	51,123	8,094,721	1,959,199	Apr 19 07:14 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 15	Sale	158.85	157,107	24,957,096	2,010,322	Apr 19 07:14 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 14	Sale	156.54	60,982	9,545,874	2,167,429	Apr 14 06:08 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 13	Sale	156.72	105,806	16,581,445	2,228,411	Apr 14 06:08 PM
MERESMAN STANLEY J	Director	Apr 12	Option Exercise	5.94	4,934	29,308	8,993	Apr 14 06:06 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 12	Sale	154.59	72,861	11,263,846	2,334,217	Apr 14 06:08 PM
MERESMAN STANLEY J	Director	Apr 12	Sale	153.74	4,934	758,533	4,059	Apr 14 06:06 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 09	Sale	156.86	60,996	9,567,678	2,407,078	Apr 09 05:51 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 08	Sale	160.78	122,846	19,751,186	2,468,074	Apr 09 05:51 PM
Eltoukhy Helmy	Chief Executive Officer	Apr 07	Sale	158.61	36,843	5,843,684	2,590,920	Apr 09 05:51 PM
Kaul Samir	Director	Apr 05	Sale	158.56	5,000	792,789	19,943	Apr 07 05:08 PM
CLARK IAN T	Director	Mar 25	Option Exercise	4.18	538	2,249	5,181	Mar 29 05:13 PM
CLARK IAN T	Director	Mar 25	Sale	132.09	538	71,064	4,643	Mar 29 05:13 PM
MERESMAN STANLEY J	Director	Mar 10	Option Exercise	5.94	4,934	29,308	8,993	Mar 12 05:25 PM
MERESMAN STANLEY J	Director	Mar 10	Sale	137.85	4,934	680,152	4,059	Mar 12 05:25 PM
CLARK IAN T	Director	Feb 25	Option Exercise	4.18	538	2,249	5,181	Mar 01 05:09 PM
CLARK IAN T	Director	Feb 25	Sale	154.00	538	82,852	4,643	Mar 01 05:09 PM
Talasaz AmirAli	Chairman, President and COO	Feb 11	Sale	168.46	6,613	1,114,042	470,800	Feb 12 08:21 PM
Talasaz AmirAli	Chairman, President and COO	Feb 11	Sale	166.56	23,529	3,918,993	477,413	Feb 12 08:19 PM
Talasaz AmirAli	Chairman, President and COO	Feb 11	Sale	166.98	202,251	33,771,358	1,725,422	Feb 12 08:19 PM
MERESMAN STANLEY J	Director	Feb 10	Option Exercise	5.94	4,934	29,308	8,993	Feb 12 04:53 PM
Talasaz AmirAli	Chairman, President and COO	Feb 10	Sale	160.90	8,689	1,398,054	500,942	Feb 12 08:19 PM
Talasaz AmirAli	Chairman, President and COO	Feb 10	Sale	160.90	58,304	9,381,070	1,927,673	Feb 12 08:19 PM
MERESMAN STANLEY J	Director	Feb 10	Sale	162.71	4,934	802,811	4,059	Feb 12 04:53 PM
Talasaz AmirAli	Chairman, President and COO	Feb 09	Sale	162.93	15,069	2,455,231	509,631	Feb 09 07:21 PM
Talasaz AmirAli	Chairman, President and COO	Feb 09	Sale	162.93	101,111	16,474,264	1,985,632	Feb 09 07:21 PM
Talasaz AmirAli	Chairman, President and COO	Feb 08	Sale	162.39	13,817	2,243,679	524,700	Feb 09 07:21 PM
Talasaz AmirAli	Chairman, President and COO	Feb 08	Sale	162.39	92,708	15,054,427	2,086,743	Feb 09 07:21 PM
Talasaz AmirAli	Chairman, President and COO	Feb 05	Sale	161.76	30,084	4,866,462	538,517	Feb 09 07:21 PM
Talasaz AmirAli	Chairman, President and COO	Feb 05	Sale	161.76	201,861	32,653,529	2,179,451	Feb 09 07:21 PM
Talasaz AmirAli	Chairman, President and COO	Feb 04	Sale	158.75	6,970	1,106,512	568,601	Feb 05 05:03 PM
Talasaz AmirAli	Chairman, President and COO	Feb 04	Sale	158.75	47,053	7,469,835	2,381,312	Feb 05 05:03 PM
Talasaz AmirAli	Chairman, President and COO	Feb 03	Sale	158.72	11,462	1,819,222	575,571	Feb 05 05:03 PM
Talasaz AmirAli	Chairman, President and COO	Feb 03	Sale	158.72	76,915	12,207,772	2,428,365	Feb 05 05:03 PM
Talasaz AmirAli	Chairman, President and COO	Feb 02	Sale	158.16	19,498	3,083,832	587,033	Feb 03 07:33 PM
Talasaz AmirAli	Chairman, President and COO	Feb 02	Sale	158.16	130,893	20,702,229	2,622,883	Feb 03 07:33 PM
Talasaz AmirAli	Chairman, President and COO	Feb 01	Sale	154.41	14,269	2,203,337	606,531	Feb 03 07:33 PM
Talasaz AmirAli	Chairman, President and COO	Feb 01	Sale	154.41	95,744	14,784,239	2,753,776	Feb 03 07:33 PM
CLARK IAN T	Director	Jan 25	Option Exercise	4.18	538	2,249	5,181	Jan 27 05:00 PM
CLARK IAN T	Director	Jan 25	Sale	162.00	538	87,156	4,643	Jan 27 05:00 PM
Eltoukhy Helmy	Chief Executive Officer	Jan 25	Sale	157.26	58,811	9,248,642	2,627,763	Jan 26 05:40 PM
Eltoukhy Helmy	Chief Executive Officer	Jan 22	Sale	159.91	102,075	16,322,404	2,686,574	Jan 26 05:40 PM
Eltoukhy Helmy	Chief Executive Officer	Jan 21	Sale	162.01	173,206	28,061,525	2,788,649	Jan 21 07:46 PM
Eltoukhy Helmy	Chief Executive Officer	Jan 20	Sale	163.53	44,528	7,281,807	365,775	Jan 21 07:46 PM
Eltoukhy Helmy	Chief Executive Officer	Jan 20	Sale	163.53	167,663	27,418,473	2,961,855	Jan 21 07:46 PM
Eltoukhy Helmy	Chief Executive Officer	Jan 19	Sale	160.12	103,717	16,606,912	410,303	Jan 21 07:46 PM
Eltoukhy Helmy	Chief Executive Officer	Jan 15	Sale	158.39	150,000	23,758,873	514,020	Jan 19 04:59 PM
MERESMAN STANLEY J	Director	Jan 11	Option Exercise	5.94	4,934	29,308	8,993	Jan 13 04:40 PM
MERESMAN STANLEY J	Director	Jan 11	Sale	142.00	4,934	700,628	4,059	Jan 13 04:40 PM
CLARK IAN T	Director	Jan 04	Option Exercise	4.18	2,690	11,244	7,333	Jan 06 04:18 PM
CLARK IAN T	Director	Jan 04	Sale	129.23	2,690	347,629	4,643	Jan 06 04:18 PM
Eltoukhy Helmy	Chief Executive Officer	Jan 01	Option Exercise	0.00	565,192	0	3,408,645	Jan 05 08:44 PM
Talasaz AmirAli	Chairman, President and COO	Jan 01	Option Exercise	0.00	565,192	0	3,128,647	Jan 05 08:42 PM
CLARK IAN T	Director	Dec 28	Option Exercise	4.18	538	2,249	5,181	Dec 30 04:30 PM
CLARK IAN T	Director	Dec 28	Sale	135.00	538	72,630	4,643	Dec 30 04:30 PM
Talasaz AmirAli	Chairman, President and COO	Dec 21	Option Exercise	4.18	23,923	99,998	2,563,455	Dec 23 04:50 PM
Eltoukhy Helmy	Chief Executive Officer	Dec 16	Option Exercise	4.18	23,923	99,998	2,843,453	Dec 18 04:57 PM
MERESMAN STANLEY J	Director	Dec 10	Option Exercise	5.94	4,954	29,427	9,013	Dec 14 04:52 PM
MERESMAN STANLEY J	Director	Dec 10	Sale	125.44	4,954	621,430	4,059	Dec 14 04:52 PM
CLARK IAN T	Director	Dec 03	Option Exercise	4.18	2,690	11,244	7,333	Dec 07 05:01 PM
CLARK IAN T	Director	Dec 03	Sale	120.00	2,690	322,800	4,643	Dec 07 05:01 PM
CLARK IAN T	Director	Nov 25	Option Exercise	4.18	538	2,249	5,181	Nov 27 02:48 PM
CLARK IAN T	Director	Nov 25	Sale	113.28	538	60,945	4,643	Nov 27 02:48 PM
MERESMAN STANLEY J	Director	Nov 10	Option Exercise	5.94	5,000	29,700	9,059	Nov 12 05:07 PM
MERESMAN STANLEY J	Director	Nov 10	Sale	110.30	5,000	551,500	4,059	Nov 12 05:07 PM
CLARK IAN T	Director	Nov 03	Option Exercise	4.18	2,690	11,244	7,333	Nov 05 05:32 PM
CLARK IAN T	Director	Nov 03	Sale	105.28	2,690	283,203	4,643	Nov 05 05:32 PM
Talasaz AmirAli	Chairman, President and COO	Oct 27	Sale	107.18	75,851	8,129,541	620,800	Oct 27 06:08 PM
CLARK IAN T	Director	Oct 26	Option Exercise	4.18	538	2,249	5,181	Oct 28 04:32 PM
CLARK IAN T	Director	Oct 26	Sale	104.03	538	55,968	4,643	Oct 28 04:32 PM
Talasaz AmirAli	Chairman, President and COO	Oct 26	Sale	105.02	4,613	484,472	696,651	Oct 27 06:08 PM
Talasaz AmirAli	Chairman, President and COO	Oct 23	Sale	105.15	13,136	1,381,315	701,264	Oct 27 06:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience